Peptide and Protein-Based Cancer Vaccines

Braun, Michel Y; Perret, Rachel; Scholz, Godehard; Romero, Pedro

doi:10.1007/978-1-4614-4732-0_5

Cited by 3 publications

(1 citation statement)

References 190 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the former display a limited immunogenicity, thus requiring the use of adjuvants. In the case of peptides, a further limitation is represented by the fact that their application is limited to patients with specific human leukocyte antigen (HLA) molecules [ 23 ]. The major drawback of gene-based vaccines is their limited uptake and consequent limited antigen transcription by transfected cells [ 24 ].…”

Section: Toward Cancer Immunoprevention: Lessons Learned From Precmentioning

confidence: 99%

The Promise of Preventive Cancer Vaccines

2015

View full text Add to dashboard Cite

Years of unsuccessful attempts at fighting established tumors with vaccines have taught us all that they are only able to truly impact patient survival when used in a preventive setting, as would normally be the case for traditional vaccines against infectious diseases. While true primary cancer prevention is still but a long-term goal, secondary and tertiary prevention are already in the clinic and providing encouraging results. A combination of immunopreventive cancer strategies and recently approved checkpoint inhibitors is a further promise of forthcoming successful cancer disease control, but prevention will require a considerable reduction of currently reported toxicities. These considerations summed with the increased understanding of tumor antigens allow space for an optimistic view of the future.

show abstract

Section: Toward Cancer Immunoprevention: Lessons Learned From Precmentioning

confidence: 99%

The Promise of Preventive Cancer Vaccines

2015

View full text Add to dashboard Cite

show abstract

Opportunities in combinational chemo-immunotherapy for breast cancer using nanotechnology: an emerging landscape

Raikwar¹,

Jain

Saraf³

et al. 2022

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Immunotherapy of cancers comes of age

Yousefi

Yuan

Keshavarz-Fathi

et al. 2017

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Cancer immunotherapy has evolved and is aimed at generating the efficacious therapeutic modality to enhance the specificity and power of the immune system to combat tumors. Areas covered: Current efforts in cancer immunotherapy fall into three main approaches. One approach is through the blockade of immune checkpoints, another approach is through adoptive cellular therapy, and the last approach is through vaccination. The goal of this review is to summarize the current understanding and status of cancer immunotherapy in these three categories. Expert commentary: We foresee the development of therapeutic protocols combining these approaches with each other or conventional therapies to achieve the most appropriate guideline for management of cancer.

show abstract

Peptide and Protein-Based Cancer Vaccines

Cited by 3 publications

References 190 publications

The Promise of Preventive Cancer Vaccines

The Promise of Preventive Cancer Vaccines

Opportunities in combinational chemo-immunotherapy for breast cancer using nanotechnology: an emerging landscape

Immunotherapy of cancers comes of age

Contact Info

Product

Resources

About